NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

559.50 16.85 (3.11%)

32.58% Gain from 52W Low

1.1M NSE+BSE Volume

NSE 03 Oct, 2025 12:28 PM (IST)

13,577.3

Market Cap

High in industry

1.4

Beta 1Year

Very High Volatility

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Granules India Ltd.

29 Jul 2021

559.50

3.11%

Granules lndia

Buy: Granules India Ltd.

Target

ICICI Securities Limited

...

Granules India Ltd. has an average target of 615.75 from 4 brokers.

Granules India Ltd.

14 May 2021

559.50

3.11%

GRANULES INDIA

Buy: Granules India Ltd.

Recommendation Target

Geojit BNP Paribas

revenues growing by 33% YoY to Rs.799cr in Q4FY21. All segments saw strong growth mainly on the back of of successful new launches, increase in market share of finished dosages, as well as customer additions for APIs and PFIs. Disruption in supply of key raw materials from China will impact operating performance in the short term The company has guided a Capex of ~Rs.1,000cr over the next 3 years as it looks to expand capacities for its key products...

Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.

Granules India Ltd.

12 May 2021

559.50

3.11%

BP Equities Granules India Ltd Q4FY21 Result Update

Buy: Granules India Ltd.

Target

BP Wealth

Healthy Q4; Input cost increase to dent margin in the near term Granules (GIL) posted revenues of INR 7993mn with 33.2% YoY growth, which was 3.7% above our estimate of INR 7710mn. Revenue growth was mainly driven by an increase in the market share of existing products, new customer additions in the API segment and increasing penetration of PFIs as a category. During Q4, FDs grew by 34% (YoY), PFIs grew by 85% (YoY) and API sales were up by 9%(YoY). Better realisations across our existing molecules and new launches contributed to the increase in gross margins by 378bps (YoY). Subsequently, the EBITDA margin expanded by 861bps to a 25.3% level was 167bps higher than our estimate. EBITDA Margin improvement was mainly on account of higher sales and volumes over a lower base of the previous year. The low base of the previous year was...

Granules India Ltd. has an average target of 615.75 from 4 brokers.

Granules India Ltd.

12 May 2021

559.50

3.11%

Strong end to FY21; on track to develop product/add capacity

Buy: Granules India Ltd.

Target

Motilal Oswal

GRAN delivered an in line performance in 4Q and posted its highest ever sales/EBITDA/PAT on an annual basis in FY21. This was largely led by strong traction in ingredients (PFIs) and formulations (FDs). While the company is on track to expand capacity/develop products, a sharp increase in prices of select key starting materials (KSM) may hinder its near-term performance. We lower our FY22E/FY23E EPS estimate by 11%/10% to factor in a price increase/reduced availability of KSM like para-aminophenol (PAP)/acetic anhydride and lower operating leverage. We value GRAN at 15x 12-months...

Granules India Ltd. has an average target of 615.75 from 4 brokers.

Granules India Ltd.

29 Jan 2021

559.50

3.11%

BP Equities Granules India Ltd Q3FY21 Result Update

Buy: Granules India Ltd.

Target

BP Wealth

Granules (GIL) posted revenues of INR 8445mn with 20% YoY growth, which was ~16% above our estimate of INR 7279mn. Revenue growth was mainly driven by increase in the market share of existing products, new customer additions in the API segment and increasing penetration of PFIs as a category. During Q3, FDs grew by 11% (YoY), PFIs grew by 48% (YoY) and API sales were up by 20%(YoY). Gross margin improved (300bps YoY) due to favourable product mix (larger share of FDs and PFIs) and higher capacity utilization. Subsequently, the EBITDA margin expanded by 188bps to 25.1% level was 145bps higher than our estimate supported by improved operational efficiency. As per management EBITDA margin can be sustained between 25% to 27% level as continued traction in the formulation business. GIL reported PAT of INR 1468mn, was above our estimate of INR 993mn...

Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.

Granules India Ltd.

29 Jan 2021

559.50

3.11%

Granules lndia

Buy: Granules India Ltd.

ICICI Securities Limited

Revenues grew 20% YoY to | 845 crore driven by new launches and higher market share of existing products across segments. Formulations grew 11% YoY to | 422 crore, API grew 20% to | 252 crore and PFI grew 48% to | 171 crore. EBITDA margins improved 187 bps YoY to 25.1% due to change in product mix and higher operational efficiency. EBITDA grew 29.7% YoY to | 212 crore. Adjusted PAT grew 52.8% YoY to | 147 crore. Delta vis-a-vis EBITDA was due to higher other income (one-time | 13.4 crore stimulus...